JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Insulin-like growth factor-binding protein 7 is up-regulated during EAE and inhibits the differentiation of oligodendrocyte precursor cells.

Oligodendrocyte precursor cells (OPCs) differentiation failure is one of the leading causes for remyelination defects in the demyelinating lesions of multiple sclerosis (MS). In this study, we explored the roles of insulin-like growth factor-binding proteins 7 (IGFBP-7) on OPCs differentiation during experimental autoimmune encephalomyelitis (EAE). We first investigated the expression pattern of IGFBP-7 by real-time PCR and immunofluorescence staining. It showed that IGFBP-7 was expressed in astrocytes (ACs), oligodendrocytes (OLs) and neurons both in vitro and in vivo. The mRNA and protein level of IGFBP-7 was also increased in the spinal cord from mice at the peak of EAE disease. Next we found that IGFBP-7 acted as a negatively regulator of the OPCs differentiation. Together, these data suggest that IGFBP-7 was up regulated during EAE and inhibit the transition from OPCs to mature OLs, implying its use as a potential therapeutic target for the treatment of inflammatory demyelinating diseases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app